Neurocrine Biosciences
NBIX
NBIX
218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
3% less funds holding
Funds holding: 225 → 218 (-7)
10% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 80
39% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $20.3M
Holders
218
Holding in Top 10
6
Calls
$12.3M
Puts
$20.3M
Top Buyers
| 1 | +$216M | |
| 2 | +$88.3M | |
| 3 | +$86.7M | |
| 4 |
Goldman Sachs
New York
|
+$43.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$31.1M |
Top Sellers
| 1 | -$80.9M | |
| 2 | -$73.1M | |
| 3 | -$51.7M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.8M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$26.5M |